letter
editor
pro
inhibitor
potenti
therapeut
option
avail
evid
ongo
clinic
trial
genu
betacoronaviru
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
histor
two
coronavirus
got
great
clinic
import
infect
human
present
novel
coronaviru
strain
caus
agent
emerg
wuhan
china
decemb
rapidli
spread
throughout
world
accord
proteas
inhibitor
lopinavirritonavir
antiinflammatori
agent
angiotensin
convert
enzym
type
ace
blocker
convalesc
plasma
rna
antisens
technolog
monoclon
antibodi
chines
tradit
medicin
http
www
chictrorgcnindexaspx
http
proteas
inhibitor
includ
lopinavir
ritonavir
current
avail
first
secondlin
antiretrovir
therapi
regimen
pediatr
adult
hivaid
patient
respect
china
nation
health
commiss
recommend
use
agent
adhoc
treatment
sinc
infect
rna
viru
similar
hiv
lopinavirritonavir
propos
manag
infect
despit
absenc
offici
approv
drug
treatment
present
lopinavirritonavir
wide
use
possibl
treatment
infect
countri
emerg
infect
exist
countri
like
belgium
prepar
interim
clinic
guidanc
treatment
patient
suspect
ofconfirm
guidelin
lopinavirritonavir
may
use
one
altern
despit
absenc
suffici
efficaci
data
http
interimguidelinestreatmentengpdf
sarscov
main
proteinas
pro
also
call
like
proteas
pro
play
key
role
proteolyt
process
viral
polyprotein
essenti
protein
viral
replic
function
consid
key
drug
target
previou
molecular
dynam
simul
analysi
indic
equaval
bind
affin
lopinavir
ritonavir
toward
sarscov
pro
addit
six
seven
hydrogen
bond
detect
sarscovlopinavir
sarscovritonavir
complex
respect
accordingli
inhibitor
block
cleavag
function
pro
expect
inhibit
viru
replic
make
enzym
one
attract
target
treatment
though
could
quit
differ
structur
lopinavir
ritonavir
may
clinic
efficaci
seen
respons
sarscov
per
china
treatment
recommend
pediatr
respiratori
infect
caus
infect
treat
combin
proteas
inhibitor
importantli
lopinavirritonavir
lpvr
per
kg
basi
andor
nebul
base
sever
case
report
regard
treatment
patient
korea
indic
administr
lpvr
patient
significantli
reduc
viral
load
littl
coronaviru
titer
observ
upon
treatment
visit
us
nation
librari
medicin
nlm
http
chines
clinic
trial
registri
http
wwwchictrorgcnindexaspx
regist
clinic
trial
retriev
total
sinc
outbreak
us
chines
clinic
trial
registri
respect
regist
trial
us
nlm
random
open
label
control
trial
wherea
remain
nonrandom
open
label
clinic
trial
supplement
tabl
regist
random
blind
placebo
control
clinic
trial
fulli
evalu
safeti
efficaci
proteas
inhibitor
real
clinic
set
till
time
review
clinic
trial
regist
china
random
open
label
clinic
trial
wherea
rest
two
nonrandom
open
label
clinic
trial
show
random
blind
placebo
control
trial
regist
yet
supplement
tabl
one
random
open
label
clinic
trial
regist
china
http
wwwchictrorgcn
showprojenaspx
trial
identifi
complet
find
publish
new
england
journal
medicin
march
state
tabl
primari
end
point
trial
clinic
improv
time
within
day
follow
random
accord
find
treatment
lopinavirritonavir
associ
differ
standard
care
time
clinic
improv
hazard
ratio
confid
interv
mortal
day
similar
lopinavirritonavir
group
standardcar
group
though
secondari
outcom
measur
found
promis
lopinavirritonavir
group
trial
initi
sever
patient
late
lack
blind
well
establish
placebo
henc
infant
conclud
poor
clinic
benefit
lopinavirritonavir
requir
random
multicent
doubl
blind
placebo
control
clinic
trial
larg
cohort
patient
stage
diseas
mild
moder
sever
fulli
investig
safeti
efficaci
drug
real
scenario
regard
recruit
statu
phase
studi
us
chines
registri
recruit
particip
two
phase
three
phase
three
phase
trial
identifi
us
clinic
trial
registri
two
phase
trial
also
identifi
chines
clinic
trial
registri
regard
intervent
trial
includ
discoveri
trial
us
chines
registri
enrol
particip
experiment
arm
proteas
inhibitor
primarili
lopinavirritonavir
one
sole
intervent
besid
total
trial
us
chines
enrol
particip
experiment
arm
proteas
inhibitor
provid
combin
agent
includ
interferon
favipiravir
chines
tradit
medicin
xiyanp
inject
convent
therapi
six
trial
us
trial
chines
registri
lopinavirritonavir
activ
compar
either
alon
combin
agent
summari
ongo
clinic
trial
includ
primari
outcom
measur
present
supplement
tabl
top
nation
institut
health
medic
research
inserm
franc
plan
initi
discoveri
trial
phase
random
open
label
clinic
trial
trial
protocol
alreadi
regist
march
avail
http
recruit
particip
start
estim
enrol
patient
arm
two
intervent
arm
lopinavirritonavir
alon
day
regimen
compar
standard
care
also
plan
launch
solidar
trial
random
open
label
recent
evalu
safeti
efficaci
lopinavirritonavir
one
intervent
arm
http
www
registr
trial
protocol
yet
commenc
till
time
review
conclus
though
sever
promis
studi
regard
mechan
action
activ
proteas
inhibitor
sarscov
suffici
vitro
vivo
studi
confid
use
use
adhoc
compassion
manner
base
case
report
previou
experi
absenc
offici
approv
drug
life
threaten
condit
even
could
taken
bench
mark
recent
publish
trial
report
suffici
earli
conclud
poor
clinic
util
lopinavirritonavir
without
conduct
multicent
random
blind
wellestablish
placebo
control
clinic
trial
conflict
declar
supplementari
materi
relat
articl
found
onlin
version
doi
http
